Page 43 Bain Capital Helthcare
P. 43
advisory heritage and tenure as healthcare and life
sciences investors, Quintiles bypassed an auction in favor
of proprietary transaction with the firm in 2008.
Bain Capital immediately began to help Quintiles’
management team think about strategic adjacencies,
about how to go further as a partner to pharmaceutical
and biotech companies, and how to win market share.
“One of those strategic moves was centered on data,” says
Chris Gordon, Co-Head of Bain Capital’s Private Equity
business and Global Head of Healthcare. “Quintiles was
sitting in the nexus of all these interesting drug trials, and
everyone wants more information on how to drive better
patient outcomes at lower costs, and how to gain better
efficacy with medication.”
Quintiles started discussions with a public company called
IMS, the leading provider of data on pharmaceutical
prescriptions. The core thesis behind the transaction
and the newly combined platform was that value to
patients, providers, pharmaceutical companies and the
overall healthcare ecosystem could be created through
the blending of clinical trial and real world data in an
integrated platform. Quintiles, by now a public company,
merged with IMS in 2013 and was renamed IQVIA. The
fully integrated and synergized company has built one of
the world’s largest portfolios of healthcare information,
with deep therapeutic, domain, regulatory and commercial
analytic expertise.
“We were able to do something that the pharmaceutical
companies couldn’t do for themselves, which was to
use data to recognize how trials can be enrolled more
quickly, and then, ultimately, to finish earlier—to bring
drugs to market in a much more rapid fashion,” says John
Connaughton, Co-Managing Partner of Bain Capital.
During the COVID crisis, IQVIA’s team has also led in dis-
seminating information and working closely with custom-
ers to alleviate the disruption of clinical trials. From the
company’s IPO in 2013 to Bain Capital’s exit in 2021, IQVIA
added nearly $1 billion in EBITDA and doubled revenue.
“The company has continued to grow on a nice trajectory
and has been able to leverage that data footprint to have
a more compelling CRO offering and vice versa,” says
Gordon.
We were able to do something that the
pharmaceutical companies couldn’t do for
themselves, which was to use data to recognize
how trials can be enrolled more quickly, and
then, ultimately, to finish earlier to bring drugs
—
to market in a much more rapid fashion.
John Connaughton
Co-Managing Partner,
Bain Capital
43
Bain Capital
Healthcare
sciences investors, Quintiles bypassed an auction in favor
of proprietary transaction with the firm in 2008.
Bain Capital immediately began to help Quintiles’
management team think about strategic adjacencies,
about how to go further as a partner to pharmaceutical
and biotech companies, and how to win market share.
“One of those strategic moves was centered on data,” says
Chris Gordon, Co-Head of Bain Capital’s Private Equity
business and Global Head of Healthcare. “Quintiles was
sitting in the nexus of all these interesting drug trials, and
everyone wants more information on how to drive better
patient outcomes at lower costs, and how to gain better
efficacy with medication.”
Quintiles started discussions with a public company called
IMS, the leading provider of data on pharmaceutical
prescriptions. The core thesis behind the transaction
and the newly combined platform was that value to
patients, providers, pharmaceutical companies and the
overall healthcare ecosystem could be created through
the blending of clinical trial and real world data in an
integrated platform. Quintiles, by now a public company,
merged with IMS in 2013 and was renamed IQVIA. The
fully integrated and synergized company has built one of
the world’s largest portfolios of healthcare information,
with deep therapeutic, domain, regulatory and commercial
analytic expertise.
“We were able to do something that the pharmaceutical
companies couldn’t do for themselves, which was to
use data to recognize how trials can be enrolled more
quickly, and then, ultimately, to finish earlier—to bring
drugs to market in a much more rapid fashion,” says John
Connaughton, Co-Managing Partner of Bain Capital.
During the COVID crisis, IQVIA’s team has also led in dis-
seminating information and working closely with custom-
ers to alleviate the disruption of clinical trials. From the
company’s IPO in 2013 to Bain Capital’s exit in 2021, IQVIA
added nearly $1 billion in EBITDA and doubled revenue.
“The company has continued to grow on a nice trajectory
and has been able to leverage that data footprint to have
a more compelling CRO offering and vice versa,” says
Gordon.
We were able to do something that the
pharmaceutical companies couldn’t do for
themselves, which was to use data to recognize
how trials can be enrolled more quickly, and
then, ultimately, to finish earlier to bring drugs
—
to market in a much more rapid fashion.
John Connaughton
Co-Managing Partner,
Bain Capital
43
Bain Capital
Healthcare
